

# Anti-CD9 [BU16]

**Catalogue number:** 151451

**Sub-type:** Primary antibody

**Images:**

## Contributor

**Inventor:**

**Institute:** University of Birmingham

**Images:**

## Tool details

**\*FOR RESEARCH USE ONLY**

**Name:** Anti-CD9 [BU16]

**Alternate name:**

**Class:** Monoclonal

**Conjugate:** Unconjugated

**Description:** CD9 antigen is a glycoprotein expressed on the surface of developing B lymphocytes, platelets, monocytes, eosinophils, basophil, stimulated T lymphocytes and neurons and glial cells in the peripheral nervous system. CD9 mediates platelet aggregation and activation via FCGR2a. It may play a role in cell migration.

**Purpose:**

**Parental cell:**

**Organism:**

**Tissue:**

**Model:**

**Gender:**

**Isotype:** IgG2a

**Reactivity:** Human

**Selectivity:**

**Host:** Mouse

**Immunogen:**

**Immunogen UNIPROT ID:**

**Sequence:**

**Growth properties:**

**Production details:**

**Formulation:**

**Recommended controls:**

**Bacterial resistance:**

**Selectable markers:**

**Additional notes:**

## Target details

**Target:** CD9

**Target alternate names:**

**Target background:** CD9 antigen is a glycoprotein expressed on the surface of developing B lymphocytes, platelets, monocytes, eosinophils, basophil, stimulated T lymphocytes and neurons and glial cells in the peripheral nervous system. CD9 mediates platelet aggregation and activation via FCGR2a. It may play a role in cell migration.

**Molecular weight:**

**Ic50:**

## Applications

**Application:** FACS ; IHC ; IF ; IP ; WB

**Application notes:**

## Handling

**Format:** Liquid

**Concentration:** 0.9-1.1 mg/ml

**Passage number:**

**Growth medium:**

**Temperature:**

**Atmosphere:**

**Volume:**

**Storage medium:**

**Storage buffer:** PBS with 0.02% azide

**Storage conditions:** -15° C to -25° C

**Shipping conditions:** Shipping at 4° C

## Related tools

**Related tools:** Anti-CD9 [P1/33/2]

## References

**References:** Leone et al. 2008. Clin Cancer Res. 14(19):6033-41. PMID: 18829482. ; Deletions of CDKN2C in multiple myeloma: biological and clinical implications. ; Velangi et al. 2004. Carcinogenesis. 25(10):1795-803. PMID: 15142887. ; DNA mismatch repair pathway defects in the pathogenesis and evolution of myeloma. ; Hamilton et al. 1991. Leukemia. 5(9):768-71. PMID: 1943229. ; Normal and neoplastic human plasma cells express bcl-2 antigen.

CancerTools.org